An identification and functional evaluation of a novel CYP2C9 variant CYP2C962
Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes. In this study, a new CYP2C9 nonsynonymous...
Saved in:
| Published in | Chemico-biological interactions Vol. 327; p. 109168 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier B.V
25.08.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes. In this study, a new CYP2C9 nonsynonymous mutation (8576C > T) was detected after the genetic screening of 162 patients took warfarin. This mutation, named as the new allele CYP2C9*62, can result in an arginine to cysteine amino acid substitution at position 125 of the CYP2C9 protein (R125C). When expressed in insect cells, the protein expression of CYP2C9.62 was significantly lower than that of the wild-type, and its metabolic activity was also significantly decreased after the addition of three typical CYP2C9 probe drugs, suggesting that the new mutant can dramatically affect the metabolism of CYP2C9 drugs in vitro. |
|---|---|
| AbstractList | Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes. In this study, a new CYP2C9 nonsynonymous mutation (8576C > T) was detected after the genetic screening of 162 patients took warfarin. This mutation, named as the new allele CYP2C9*62, can result in an arginine to cysteine amino acid substitution at position 125 of the CYP2C9 protein (R125C). When expressed in insect cells, the protein expression of CYP2C9.62 was significantly lower than that of the wild-type, and its metabolic activity was also significantly decreased after the addition of three typical CYP2C9 probe drugs, suggesting that the new mutant can dramatically affect the metabolism of CYP2C9 drugs in vitro. Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes. In this study, a new CYP2C9 nonsynonymous mutation (8576C > T) was detected after the genetic screening of 162 patients took warfarin. This mutation, named as the new allele CYP2C9*62, can result in an arginine to cysteine amino acid substitution at position 125 of the CYP2C9 protein (R125C). When expressed in insect cells, the protein expression of CYP2C9.62 was significantly lower than that of the wild-type, and its metabolic activity was also significantly decreased after the addition of three typical CYP2C9 probe drugs, suggesting that the new mutant can dramatically affect the metabolism of CYP2C9 drugs in vitro.Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within populations, and the dose is closely related to the genetic polymorphisms of the CYP2C9 and VKORC1 genes. In this study, a new CYP2C9 nonsynonymous mutation (8576C > T) was detected after the genetic screening of 162 patients took warfarin. This mutation, named as the new allele CYP2C9*62, can result in an arginine to cysteine amino acid substitution at position 125 of the CYP2C9 protein (R125C). When expressed in insect cells, the protein expression of CYP2C9.62 was significantly lower than that of the wild-type, and its metabolic activity was also significantly decreased after the addition of three typical CYP2C9 probe drugs, suggesting that the new mutant can dramatically affect the metabolism of CYP2C9 drugs in vitro. |
| ArticleNumber | 109168 |
| Author | Zhou, Quan Lü, You Yang, Jie-Fu Dai, Da-Peng Zhou, Shan Cai, Jian-Ping Geng, Pei-Wu Liu, Jian Wu, Hua-Lan Chen, Hao Wang, Shuang-Hu Chong, Jia |
| Author_xml | – sequence: 1 givenname: Hao surname: Chen fullname: Chen, Hao organization: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 2 givenname: Da-Peng surname: Dai fullname: Dai, Da-Peng organization: The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 3 givenname: Shan surname: Zhou fullname: Zhou, Shan organization: The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 4 givenname: Jian surname: Liu fullname: Liu, Jian organization: The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 5 givenname: Shuang-Hu surname: Wang fullname: Wang, Shuang-Hu organization: The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, Zhejiang Province, 323000, PR China – sequence: 6 givenname: Hua-Lan surname: Wu fullname: Wu, Hua-Lan organization: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 7 givenname: Quan surname: Zhou fullname: Zhou, Quan organization: The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, Zhejiang Province, 323000, PR China – sequence: 8 givenname: Pei-Wu surname: Geng fullname: Geng, Pei-Wu organization: The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui, Zhejiang Province, 323000, PR China – sequence: 9 givenname: Jia surname: Chong fullname: Chong, Jia organization: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 10 givenname: You surname: Lü fullname: Lü, You organization: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 11 givenname: Jian-Ping surname: Cai fullname: Cai, Jian-Ping email: caijp61@vip.sina.com organization: The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China – sequence: 12 givenname: Jie-Fu surname: Yang fullname: Yang, Jie-Fu email: yangjiefu2011@126.com organization: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, 100730, PR China |
| BookMark | eNp9kD1PwzAQhi1UJNrCD2DLyJLiOK4_xFRFfEkVMMDAZLnOWXKV2sVOIvHvSUgnBqbTq3ufk-5ZoJkPHhC6LvCqwAW73a_Mzq0IJmOWBRNnaF4ITnLOBZuhOcZY5oRLfoEWKe2HiAnFc_Sy8ZmrwbfOOqNbF3ymfZ3Zzpsx6CaDXjfdtAk205kPPTRZ9flGKpn1Ojrt21Nk5BKdW90kuDrNJfp4uH-vnvLt6-NztdnmppSszUFaUVuQEpgsKdd2x03JACShUktaUmHWRNNSl4SvGdb1rmRrgbGxtbAMk3KJbqa7xxi-OkitOrhkoGm0h9AlRWhBpBCC4qFaTFUTQ0oRrDpGd9DxWxVYje7UXg3u1OhOTe4Ghv9hjGt_HbRRu-Zf8m4iYfi-dxBVMg68gdpFMK2qg_uH_gFKhIi0 |
| CitedBy_id | crossref_primary_10_1002_cpt_2333 crossref_primary_10_3389_fendo_2023_1139805 crossref_primary_10_3390_jpm11020094 crossref_primary_10_3389_fphar_2023_1186824 crossref_primary_10_3389_fcvm_2022_1052521 crossref_primary_10_1002_prp2_718 crossref_primary_10_3389_fphar_2022_1007268 |
| Cites_doi | 10.1124/dmd.115.063412 10.3109/00498254.2013.820007 10.1111/1755-5922.12230 10.1177/1074248419843530 10.1038/tpj.2013.41 10.1038/tpj.2013.2 10.1254/jphs.13189FP 10.1016/j.jsps.2019.01.011 10.1124/jpet.105.091181 10.1055/s-0032-1328891 10.2217/pgs-2018-0146 10.2217/pgs-2016-0154 10.2217/pgs-2018-0189 10.2217/pgs.15.89 10.1021/tx700079z 10.1517/17425255.2012.657626 10.1038/aps.2013.123 10.1177/1076029616683046 10.1038/s41598-019-49329-0 10.2217/pgs-2018-0143 |
| ContentType | Journal Article |
| Copyright | 2020 Copyright © 2020. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2020 – notice: Copyright © 2020. Published by Elsevier B.V. |
| DBID | AAYXX CITATION 7X8 |
| DOI | 10.1016/j.cbi.2020.109168 |
| DatabaseName | CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Biology |
| EISSN | 1872-7786 |
| ExternalDocumentID | 10_1016_j_cbi_2020_109168 S0009279720304658 |
| GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 5GY 5RE 5VS 6J9 7-5 71M 8P~ 9JM AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AATCM AAXUO ABFRF ABFYP ABJNI ABLST ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AIEXJ AIKHN AITUG AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLECG BLXMC CS3 DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KCYFY KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPCBC SSJ SSP SSZ T5K WH7 ~G- .GJ 3O- 53G AAQXK AATTM AAXKI AAYJJ AAYWO AAYXX ABEFU ABFNM ABWVN ABXDB ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN AEIPS AEUPX AFFNX AFJKZ AFPUW AGCQF AGQPQ AGRNS AHHHB AI. AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CITATION EJD FEDTE FGOYB G-2 HMT HVGLF HZ~ H~9 R2- RIG SEW SPT SSH VH1 WUQ ZGI ZXP 7X8 EFKBS |
| ID | FETCH-LOGICAL-c396t-e9f8dfe99e69347afb7c36ee9249a94348c52a43a327560adb365800cfd8f6023 |
| IEDL.DBID | .~1 |
| ISSN | 0009-2797 1872-7786 |
| IngestDate | Mon Jul 21 11:25:46 EDT 2025 Tue Jul 01 03:41:33 EDT 2025 Thu Apr 24 22:59:32 EDT 2025 Fri Feb 23 02:46:54 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Drug metabolism CYP2C9 Functional analysis in vitro Allelic variant |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c396t-e9f8dfe99e69347afb7c36ee9249a94348c52a43a327560adb365800cfd8f6023 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 2412988840 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2412988840 crossref_primary_10_1016_j_cbi_2020_109168 crossref_citationtrail_10_1016_j_cbi_2020_109168 elsevier_sciencedirect_doi_10_1016_j_cbi_2020_109168 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-25 |
| PublicationDateYYYYMMDD | 2020-08-25 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationTitle | Chemico-biological interactions |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Zhang, Tian, Huang, Huang, Chai, Shen (bib21) 2017; 35 Chaidaroglou, Kanellopoulou, Panopoulos, Stavridis, Degiannis (bib20) 2019; 20 Wang, Pan, Dai, Wang, Geng, Cai, Hu (bib14) 2014; 44 Lee, Borgiani, Johansson, Oteri, Mkrtchian, Falconi, Ingelman-Sundberg (bib23) 2014; 14 Al-Eitan, Almasri, Khasawneh (bib4) 2019; 27 Rendic (bib16) 2002; 34 DeLozier, Lee, Coulter, Goh, Goldstein (bib22) 2005; 315 Guengerich (bib15) 2008; 21 Waring (bib8) 2019 Chen, Shao, Gong, Luo, Wang, Shi, Tan, Chen, Zhang, Hui, Wang (bib24) 2014; 9 Mak, Lam, Pineda, Lou, Xu, Meeks, Lin, Stone, Rodgers, Mitani (bib1) 2019; 24 McGraw, Waller (bib6) 2012; 8 Dai, Wang, Wang, Geng, Hu, Hu, Cai (bib13) 2013; 34 Luo, Li, Dai, Wang, Wang, Geng, Cai, Jiang, Pu, Shang, Yuan, Cao, Hu, Cai (bib9) 2014; 125 Shendre, Dillon, Limdi (bib18) 2018; 19 Ma, Cheng, Wang, Khalighi, Khalighi (bib2) 2019; 9 Dorji, Tshering, Na-Bangchang (bib5) 2019; 44 Gaikwad, Ghosh, Avery, Kamali, Shetty (bib17) 2018; 24 Claudio-Campos, Gonzalez-Santiago, Renta, Rodriguez, Carrasquillo, Gaedigk, Roche, Duconge (bib12) 2019; 20 Fung, Patsopoulos, Belknap, O'Rourke, Robb, Anderson, Shworak, Moore (bib25) 2012; 38 Miklosz, Kalaska, Mogielnicki (bib3) 2018; 69 Dai, Xu, Hu, Wang, Geng, Yang, Yang, Qian, Wang, Zhu, Zhang, Ge, Hu, Cai (bib7) 2014; 14 Dai, Wang, Li, Geng, Cai, Wang, Hu, Cai (bib10) 2015; 43 Dai, Li, Wang, Cai, Geng, Zhou, Hu, Cai (bib11) 2015; 16 Wen, Chang, Lee, Chen, Hung, Chang, Liou, Chen, Chang, Wang, Jeng, Chuang, Chen, Chen, Wu, Chen, Lee (bib19) 2017; 18 Ma (10.1016/j.cbi.2020.109168_bib2) 2019; 9 DeLozier (10.1016/j.cbi.2020.109168_bib22) 2005; 315 Dai (10.1016/j.cbi.2020.109168_bib7) 2014; 14 Lee (10.1016/j.cbi.2020.109168_bib23) 2014; 14 Gaikwad (10.1016/j.cbi.2020.109168_bib17) 2018; 24 McGraw (10.1016/j.cbi.2020.109168_bib6) 2012; 8 Dai (10.1016/j.cbi.2020.109168_bib13) 2013; 34 Dorji (10.1016/j.cbi.2020.109168_bib5) 2019; 44 Chen (10.1016/j.cbi.2020.109168_bib24) 2014; 9 Wen (10.1016/j.cbi.2020.109168_bib19) 2017; 18 Guengerich (10.1016/j.cbi.2020.109168_bib15) 2008; 21 Shendre (10.1016/j.cbi.2020.109168_bib18) 2018; 19 Al-Eitan (10.1016/j.cbi.2020.109168_bib4) 2019; 27 Dai (10.1016/j.cbi.2020.109168_bib10) 2015; 43 Mak (10.1016/j.cbi.2020.109168_bib1) 2019; 24 Claudio-Campos (10.1016/j.cbi.2020.109168_bib12) 2019; 20 Fung (10.1016/j.cbi.2020.109168_bib25) 2012; 38 Chaidaroglou (10.1016/j.cbi.2020.109168_bib20) 2019; 20 Waring (10.1016/j.cbi.2020.109168_bib8) 2019 Rendic (10.1016/j.cbi.2020.109168_bib16) 2002; 34 Miklosz (10.1016/j.cbi.2020.109168_bib3) 2018; 69 Luo (10.1016/j.cbi.2020.109168_bib9) 2014; 125 Dai (10.1016/j.cbi.2020.109168_bib11) 2015; 16 Zhang (10.1016/j.cbi.2020.109168_bib21) 2017; 35 Wang (10.1016/j.cbi.2020.109168_bib14) 2014; 44 |
| References_xml | – volume: 315 start-page: 1085 year: 2005 end-page: 1090 ident: bib22 article-title: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians publication-title: J. Pharmacol. Exp. Therapeut. – volume: 8 start-page: 371 year: 2012 end-page: 382 ident: bib6 article-title: Cytochrome P450 variations in different ethnic populations publication-title: Expet Opin. Drug Metabol. Toxicol. – volume: 21 start-page: 70 year: 2008 end-page: 83 ident: bib15 article-title: Cytochrome p450 and chemical toxicology publication-title: Chem. Res. Toxicol. – volume: 19 start-page: 1357 year: 2018 end-page: 1371 ident: bib18 article-title: Pharmacogenetics of warfarin dosing in patients of African and European ancestry publication-title: Pharmacogenomics – volume: 16 start-page: 1475 year: 2015 end-page: 1486 ident: bib11 article-title: Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient publication-title: Pharmacogenomics – volume: 20 start-page: 3 year: 2019 end-page: 8 ident: bib12 article-title: CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements publication-title: Pharmacogenomics – volume: 27 start-page: 484 year: 2019 end-page: 490 ident: bib4 article-title: Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy publication-title: Saudi Pharmaceut. J. – volume: 43 start-page: 1246 year: 2015 end-page: 1249 ident: bib10 article-title: Identification and functional assessment of a new CYP2C9 allelic variant CYP2C9*59 publication-title: Drug Metab. Dispos. – volume: 34 year: 2002 ident: bib16 article-title: Summary of information on human CYP enzymes: human P450 metabolism data publication-title: Drug Metab. Rev. – volume: 14 start-page: 85 year: 2014 end-page: 92 ident: bib7 article-title: CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database publication-title: Pharmacogenomics J. – volume: 34 start-page: 1449 year: 2013 end-page: 1456 ident: bib13 article-title: In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population publication-title: Acta Pharmacol. Sin. – volume: 9 year: 2014 ident: bib24 article-title: A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients publication-title: PloS One – volume: 69 year: 2018 ident: bib3 article-title: Pharmacogenetic considerations of anticoagulant medication publication-title: J. Physiol. Pharmacol. – volume: 44 start-page: 270 year: 2014 end-page: 275 ident: bib14 article-title: Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro publication-title: Xenobiotica – volume: 35 start-page: 26 year: 2017 end-page: 32 ident: bib21 article-title: Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis publication-title: Cardiovasc Ther. – volume: 24 start-page: 353 year: 2018 end-page: 359 ident: bib17 article-title: Warfarin dose model for the prediction of stable maintenance dose in Indian patients publication-title: Clin. Appl. Thromb. Hemost. – volume: 24 start-page: 521 year: 2019 end-page: 533 ident: bib1 article-title: Pharmacogenetics of warfarin in a diverse patient population publication-title: J. Cardiovasc. Pharmacol. Therapeut. – volume: 18 start-page: 245 year: 2017 end-page: 253 ident: bib19 article-title: Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial publication-title: Pharmacogenomics – volume: 44 start-page: 508 year: 2019 end-page: 524 ident: bib5 article-title: CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review publication-title: J. Clin. Pharm. Therapeut. – volume: 125 start-page: 150 year: 2014 end-page: 156 ident: bib9 article-title: Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient publication-title: J. Pharmacol. Sci. – volume: 20 start-page: 311 year: 2019 end-page: 317 ident: bib20 article-title: Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype publication-title: Pharmacogenomics – volume: 9 start-page: 12856 year: 2019 ident: bib2 article-title: Clinical model for predicting warfarin sensitivity publication-title: Sci. Rep. – start-page: 1 year: 2019 end-page: 10 ident: bib8 article-title: Cytochrome P450: genotype to phenotype – volume: 14 start-page: 343 year: 2014 end-page: 349 ident: bib23 article-title: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase publication-title: Pharmacogenomics J. – volume: 38 start-page: 893 year: 2012 end-page: 904 ident: bib25 article-title: Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin publication-title: Semin. Thromb. Hemost. – volume: 43 start-page: 1246 issue: 8 year: 2015 ident: 10.1016/j.cbi.2020.109168_bib10 article-title: Identification and functional assessment of a new CYP2C9 allelic variant CYP2C9*59 publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.115.063412 – volume: 9 issue: 8 year: 2014 ident: 10.1016/j.cbi.2020.109168_bib24 article-title: A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients publication-title: PloS One – volume: 44 start-page: 270 issue: 3 year: 2014 ident: 10.1016/j.cbi.2020.109168_bib14 article-title: Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro publication-title: Xenobiotica doi: 10.3109/00498254.2013.820007 – start-page: 1 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib8 – volume: 35 start-page: 26 issue: 1 year: 2017 ident: 10.1016/j.cbi.2020.109168_bib21 article-title: Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: a systematic review and meta-analysis publication-title: Cardiovasc Ther. doi: 10.1111/1755-5922.12230 – volume: 34 issue: 1–2 year: 2002 ident: 10.1016/j.cbi.2020.109168_bib16 article-title: Summary of information on human CYP enzymes: human P450 metabolism data publication-title: Drug Metab. Rev. – volume: 24 start-page: 521 issue: 6 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib1 article-title: Pharmacogenetics of warfarin in a diverse patient population publication-title: J. Cardiovasc. Pharmacol. Therapeut. doi: 10.1177/1074248419843530 – volume: 14 start-page: 343 issue: 4 year: 2014 ident: 10.1016/j.cbi.2020.109168_bib23 article-title: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase publication-title: Pharmacogenomics J. doi: 10.1038/tpj.2013.41 – volume: 14 start-page: 85 issue: 1 year: 2014 ident: 10.1016/j.cbi.2020.109168_bib7 article-title: CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database publication-title: Pharmacogenomics J. doi: 10.1038/tpj.2013.2 – volume: 125 start-page: 150 issue: 2 year: 2014 ident: 10.1016/j.cbi.2020.109168_bib9 article-title: Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient publication-title: J. Pharmacol. Sci. doi: 10.1254/jphs.13189FP – volume: 27 start-page: 484 issue: 4 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib4 article-title: Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy publication-title: Saudi Pharmaceut. J. doi: 10.1016/j.jsps.2019.01.011 – volume: 315 start-page: 1085 issue: 3 year: 2005 ident: 10.1016/j.cbi.2020.109168_bib22 article-title: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians publication-title: J. Pharmacol. Exp. Therapeut. doi: 10.1124/jpet.105.091181 – volume: 44 start-page: 508 issue: 4 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib5 article-title: CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review publication-title: J. Clin. Pharm. Therapeut. – volume: 38 start-page: 893 issue: 8 year: 2012 ident: 10.1016/j.cbi.2020.109168_bib25 article-title: Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin publication-title: Semin. Thromb. Hemost. doi: 10.1055/s-0032-1328891 – volume: 19 start-page: 1357 issue: 17 year: 2018 ident: 10.1016/j.cbi.2020.109168_bib18 article-title: Pharmacogenetics of warfarin dosing in patients of African and European ancestry publication-title: Pharmacogenomics doi: 10.2217/pgs-2018-0146 – volume: 18 start-page: 245 issue: 3 year: 2017 ident: 10.1016/j.cbi.2020.109168_bib19 article-title: Pharmacogenetic dosing of warfarin in the Han-Chinese population: a randomized trial publication-title: Pharmacogenomics doi: 10.2217/pgs-2016-0154 – volume: 20 start-page: 311 issue: 5 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib20 article-title: Extremely low therapeutic doses of acenocoumarol in a patient with CYP2C9*3/*3 and VKORC1-1639A/A genotype publication-title: Pharmacogenomics doi: 10.2217/pgs-2018-0189 – volume: 16 start-page: 1475 issue: 13 year: 2015 ident: 10.1016/j.cbi.2020.109168_bib11 article-title: Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient publication-title: Pharmacogenomics doi: 10.2217/pgs.15.89 – volume: 21 start-page: 70 issue: 1 year: 2008 ident: 10.1016/j.cbi.2020.109168_bib15 article-title: Cytochrome p450 and chemical toxicology publication-title: Chem. Res. Toxicol. doi: 10.1021/tx700079z – volume: 8 start-page: 371 issue: 3 year: 2012 ident: 10.1016/j.cbi.2020.109168_bib6 article-title: Cytochrome P450 variations in different ethnic populations publication-title: Expet Opin. Drug Metabol. Toxicol. doi: 10.1517/17425255.2012.657626 – volume: 69 issue: 4 year: 2018 ident: 10.1016/j.cbi.2020.109168_bib3 article-title: Pharmacogenetic considerations of anticoagulant medication publication-title: J. Physiol. Pharmacol. – volume: 34 start-page: 1449 issue: 11 year: 2013 ident: 10.1016/j.cbi.2020.109168_bib13 article-title: In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population publication-title: Acta Pharmacol. Sin. doi: 10.1038/aps.2013.123 – volume: 24 start-page: 353 issue: 2 year: 2018 ident: 10.1016/j.cbi.2020.109168_bib17 article-title: Warfarin dose model for the prediction of stable maintenance dose in Indian patients publication-title: Clin. Appl. Thromb. Hemost. doi: 10.1177/1076029616683046 – volume: 9 start-page: 12856 issue: 1 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib2 article-title: Clinical model for predicting warfarin sensitivity publication-title: Sci. Rep. doi: 10.1038/s41598-019-49329-0 – volume: 20 start-page: 3 issue: 1 year: 2019 ident: 10.1016/j.cbi.2020.109168_bib12 article-title: CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements publication-title: Pharmacogenomics doi: 10.2217/pgs-2018-0143 |
| SSID | ssj0000240 |
| Score | 2.3386803 |
| Snippet | Warfarin is the most commonly used anticoagulant in the clinical treatment of thromboembolic diseases. The dose of warfarin varies significantly within... |
| SourceID | proquest crossref elsevier |
| SourceType | Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 109168 |
| SubjectTerms | Allelic variant CYP2C9 Drug metabolism Functional analysis in vitro |
| Title | An identification and functional evaluation of a novel CYP2C9 variant CYP2C962 |
| URI | https://dx.doi.org/10.1016/j.cbi.2020.109168 https://www.proquest.com/docview/2412988840 |
| Volume | 327 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6iiF7EJ76JIB6Eapu0aXJci7IqLh4U9BSSNIEV7Yqughd_u5m0URTx4K1p01Jmwsx8mck3CO3WTGluNU9qZzSkGdOEZzRLdCY0YURTGni2Lwasf52f3RQ3E6iKZ2GgrLKz_a1ND9a6u3PYSfPwcTiEM76pIKWAPKIHeQUc-M3zElb5wftXmQdweMVuajA7ZjZDjZfRQw8RSSBVyoBt9Xff9MNKB9dzMo_mupgR99rfWkATtllES73G4-WHN7yHQxVn2B5fRNNH8Wqmir3cltCg1-Bh3RUGBV1g1dQYnFq7F4i_WL_xyGGFm9GrvcfV7SWpBH71gNproBsysoyuT46vqn7SdVJIDBVsnFjheO2sEJYJmpfK6dJQZi2ALwUMcdwUROVUUWCDT1WtqRdomhpXc8e8W19Bk82osasI54z654X1oYrJGTcaEEpWE6Zd6azVayiNMpSmoxmHbhf3MtaT3Ukvdglil63Y19D-5yuPLcfGX5PzqBj5baFI7wP-em0nKlF62UNWRDV29PIsfQhDBOce6K7_79MbaBZGsNFMik00OX56sVs-Uhnr7bAUt9FU7_S8P_gA0frkCg |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3PTxQxFG4IxuDFCGhEEWuiHkxGZtqZbnvwsK6SRWDjARI81bbTJktwlsAC4cI_5T_oe51WojEcTLjNTKczk-913o_29XuEvG6FsdJbWbTBWVxmLAtZ8aqwlbJMMMt55Nnem4jxQf3lsDlcID_zXhhMq0y6v9fpUVunK5sJzc2T6RT3-JaKDRSuI0KQ18iUWbnjry4hbjv7sP0JhPyGsa3P-6NxkUoLFI4rMS-8CrINXikvFK8HJtiB48J7jEYMUqZJ1zBTc8ORHr00reXwhrJ0oZVBRLYD0Pv3alAXWDbh_fVNXgmShuXybfh5eSk1JpU5O4WYlEUWpwrpXf9tDP8yC9HWbT0iD5OTSoc9DstkwXcrZHXYQYD-44q-pTFtNM7Hr5D7H_PR0igXj1slk2FHp23KRIrCp6ZrKVrRfvKR3tCM01mghnazC39MR9--spGiFxDBg8jTqWCPycGd4PuELHazzj8ltBYc2hsPvpGrhXQWQ6KqZcKGQfDerpEyY6hd4jXH8hrHOiewHWmAXSPsuod9jbz73eWkJ_W47eY6C0b_MTI1GJ3bur3KQtSAPS7DmM7Pzs80-ExMSQmR9bP_e_RLsjTe39vVu9uTnefkAbbgLDdr1sni_PTcvwA3aW434rCk5Ptd_we_AAWiH2k |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+identification+and+functional+evaluation+of+a+novel+CYP2C9+variant+CYP2C962&rft.jtitle=Chemico-biological+interactions&rft.au=Chen%2C+Hao&rft.au=Dai%2C+Da-Peng&rft.au=Zhou%2C+Shan&rft.au=Liu%2C+Jian&rft.date=2020-08-25&rft.issn=1872-7786&rft.eissn=1872-7786&rft.volume=327&rft.spage=109168&rft_id=info:doi/10.1016%2Fj.cbi.2020.109168&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-2797&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-2797&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-2797&client=summon |